by mpzzqmvj | Feb 3, 2022 | Press Releases
– Company’s pivotal Phase 3 study, TransportNPC™, ongoing with global site activation and patient enrollment underway – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with...
by mpzzqmvj | Jan 20, 2022 | Press Releases
– Live video webcast presentation on Thursday, January 27th at 10:00 AM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to...
by mpzzqmvj | Dec 9, 2021 | Press Releases
– Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal...
by mpzzqmvj | Dec 6, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Nov 17, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients...
